Clinical trials · Hartford, CT
Advanced Solid Tumor clinical trials in Hartford
We’re tracking 102 recruiting advanced solid tumor studies with a site in or near Hartford — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Hartford
- NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Hartford, ConnecticutAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Hartford, ConnecticutAges 12 years+ - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
Hartford, ConnecticutAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Hartford, ConnecticutAges 18–80 - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Hartford, ConnecticutAges Any age - NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
Plainville, ConnecticutAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Springfield, MassachusettsAges Any age - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
North Haven, ConnecticutAges 18 years+ - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
North Haven, ConnecticutAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New Haven, ConnecticutAges 18 years+ - NCT06414460RecruitingPhase 1/Phase 2
ISM3412 for advanced solid tumors with MTAP deletion
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
New Haven, ConnecticutAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
New Haven, ConnecticutAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
New Haven, ConnecticutAges 1 month–17 years - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
New Haven, ConnecticutAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
New Haven, ConnecticutAges 18 years+ - NCT07205718RecruitingPhase 1/Phase 2
Study of TAK-188 for advanced solid tumors
This trial tests a new medicine, TAK-188, for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07222267RecruitingPhase 1
Study of BG-75202 for advanced solid tumors
This trial tests a new drug called BG-75202, alone or with other drugs, for people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. It may offer a new option when other treatments have failed.
New Haven, ConnecticutAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
New Haven, ConnecticutAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+
Hear when a new Advanced Solid Tumor trial opens near Hartford, CT
We’ll email you when one opens near Hartford, CT — at most once a week, no account needed, unsubscribe anytime.
Advanced Solid Tumor trials in other cities
Where these studies are running near Hartford
Institutions with a site for the recruiting advanced solid tumor studies listed above.
- Yale University · 7 studies
- Yale Cancer Center · 2 studies
- Avenzo Therapeutics Recruiting Site
- Baystate Medical Center
- Charlotte Hungerford
- Hartford Healthcare
- Hartford Healthcare (Data Collection)
- Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut
What taking part in a advanced solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced solid tumor studies in Connecticut.
Common questions
- Are there advanced solid tumor clinical trials near Hartford?
- Yes. We're currently tracking 102 recruiting advanced solid tumor studies with a site near Hartford, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced solid tumor study near Hartford?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Hartford to take part?
- Not necessarily. These studies have a site near Hartford, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced solid tumor studies open near Hartford regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.